PTAB Upholds Five Pfizer, UCB Patents for Toviaz

Generic Line
A A
The PTO’s Patent Trial and Appeal Board rejected five Mylan challenges to patents held by UCB Pharma and Pfizer covering the overactive bladder treatment Toviaz.

To View This Article:

Login

Subscribe To Generic Line